Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Metastatic Triple-negative Breast Cancer
Interventions: DRUG: Sacituzumab Govitecan-hziy
Sponsor: Gilead Sciences